



HEMOPHILIA A/ HEMOPHILIA B

MANAGEMENT IN SPECIAL POPULATIONS

With advances in hemophilia treatment options, medical decision-making also must progress, from acute care to chronic care...



...and from a strictly biomedical model to a more complex model, including a psychosocial consideration of the patient's experience and SDM.



Diverse populations may face difficulties in fully participating in SDM due to several reasons beyond strictly language barriers and/or health literacy.

SDM in special populations also requires other considerations:



Gender and culture



Health disparities



Insurance and financial barriers



Psychosocial considerations



Gender and Cultural Sensitivity

- Women with hemophilia may face **underdiagnosis and limited access to care** due to gender bias.
- **Cultural norms and values** influence the decision-making process, potentially leading to miscommunication or misunderstanding



Health Disparities

- Minorities may experience **unequal access to healthcare resources** or face **systemic barriers** that impact the quality of care
- **Socioeconomic factors**, including **lack of insurance**, often exacerbate disparities in hemophilia treatment and care



Insurance and Financial Barriers

- Patients with **limited or no insurance** may struggle to access necessary treatments, leading to suboptimal care
- **High costs of factor replacement therapy** and other treatments can create challenges in treatment adherence and long-term care management



Psychosocial Considerations

- **Stigma and misconceptions** surrounding hemophilia, especially in marginalized communities, can affect patient willingness to seek care
- Addressing **emotional and psychological needs** of patients from diverse backgrounds is crucial for effective SDM

Strategies for Improved Care in Special Populations

- Use of interpreters and culturally competent care models
- Flexible treatment options and financial assistance programs
- Empowering patients with knowledge and support to make informed decisions



Healthcare providers must be trained to address the unique needs of different populations to ensure **all patients with hemophilia are actively involved in their care decisions.**



The Haemo-QoL, Haem-A-QoL, and Hemo-Sat instruments have been culturally adapted and linguistically validated into multiple languages to accurately assess health-related quality of life and treatment satisfaction among diverse patient populations.

Importantly, incorporating SDM and consideration of special populations does not require compromising evidence-based medical decision-making.

All images shown are for educational purposes only.

Abbreviations

Haem-A-QoL: Haemophilia Quality of Life Questionnaire for Adults
Haemo-QoL: Quality of Life of Children with Haemophilia in Europe
Hemo-Sat: Hemophilia Patient Satisfaction Scale
SDM: shared decision-making

Additional Resources

Byams VR, et al. *Expert Rev Hematology*. 2023;16(suppl 1): 87-106. doi:10.1080/17474086.2023.2183836

Colorito R. *Hemaware Magazine*. <https://hemaware.org/community-pulse/recognizing-racial-and-ethnic-health-disparities-black-and-latinx-communities>

Norris KL, et al. *Health Equity*. 2025;9. doi:10.1089/heq.2024.0146

The National Bleeding Disorders Foundation. Health access and strategic innovation. 2025. <https://www.bleeding.org/who-we-are/our-story/health-access>